Welcome to our dedicated page for Amylyx Pharmaceuticals news (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals stock.
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a biopharmaceutical company focused on investigational therapies for neurodegenerative and endocrine diseases, and its news flow reflects the progress and setbacks typical of clinical-stage drug development. Company updates frequently highlight milestones in its pipeline, including avexitide for post-bariatric hypoglycemia (PBH), AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis (ALS), and AMX0318 as a long-acting GLP-1 receptor antagonist candidate.
Investors following AMLX news can expect regular announcements on clinical trial progress, such as enrollment status, early safety and tolerability data, and biomarker analyses from studies like the Phase 3 LUCIDITY trial in PBH and the Phase 1 LUMINA trial in ALS. Amylyx also issues press releases when it reports financial results, providing context on research and development spending, cash runway, and the anticipated timing of key clinical and regulatory milestones.
Another recurring news theme is regulatory and program updates, including FDA designations, decisions to advance or discontinue specific programs, and detailed descriptions of conditions such as PBH, ALS, PSP, and Wolfram syndrome. The company has, for example, communicated its decision to discontinue the ORION program of AMX0035 in progressive supranuclear palsy after Phase 2b results, while continuing development of AMX0035 in Wolfram syndrome.
Amylyx also announces capital markets events and investor outreach, such as underwritten public offerings of common stock and participation in healthcare and biopharma conferences. For readers tracking AMLX, this news page offers a consolidated view of clinical, financial, and strategic disclosures that shape the company’s development trajectory. Bookmarking this feed can help investors and observers monitor how Amylyx’ investigational therapies advance through trials and how management communicates key developments.
Amylyx Pharmaceuticals has appointed Masako Nakamura as General Manager and Head of International Markets for Asia Pacific and Latin America. With over 30 years of experience in the biopharmaceutical industry, she aims to enhance the global reach of AMX0035, also known as RELYVRIO in the U.S. and ALBRIOZA in Canada. The company is progressing with regulatory discussions in Europe following a strong commercial launch in the U.S. and Canada. Nakamura's leadership is expected to advance Amylyx's mission of delivering innovative therapies for amyotrophic lateral sclerosis (ALS) and addressing unmet needs in neurodegenerative diseases.
Amylyx Pharmaceuticals (NASDAQ: AMLX) has initiated dosing for the HELIOS study, a Phase 2 clinical trial of AMX0035 aimed at treating Wolfram syndrome (WS). The trial assesses the safety, tolerability, and various health functions related to WS. Initial preclinical data demonstrated the potential of AMX0035, showing improved WFS1 protein expression and delayed onset of diabetes in a mouse model. The findings were published in the Journal of Clinical Investigation Insight. The FDA granted orphan drug designation to AMX0035 in November 2020, enabling potential market exclusivity and financial incentives. Topline results from the HELIOS study are expected in 2024, addressing a critical unmet need in the WS community.
Amylyx Pharmaceuticals, Inc. (AMLX) announced participation in the 22nd Annual Needham Virtual Healthcare Conference. Co-CEOs Joshua Cohen and Justin Klee will present on April 18, 2023, at 12:45 PM ET. Investors can access a live webcast of the event through the company’s investor relations page, with a replay available for 90 days post-event.
Amylyx focuses on innovative treatments for neurodegenerative diseases, headquartered in Cambridge, Massachusetts, with operations in Canada and EMEA. For more details, visit the company's website.
Amylyx Pharmaceuticals reported full-year 2022 product revenue of $22.2 million, primarily from the launches of RELYVRIO® in the U.S. and ALBRIOZA™ in Canada. In Q4 2022, net product revenue was $21.9 million, while the net loss for the quarter increased to $42.7 million or $0.65 per share. The company announced the appointment of Karen Firestone to its Board of Directors and emphasized upcoming regulatory reviews in the EU. Despite strong launch engagement and ongoing Phase 3 trials, the company is aware of the challenges that lie ahead in expanding access for ALS patients.
Amylyx Pharmaceuticals (NASDAQ: AMLX) announced participation in two upcoming virtual investor conferences. Co-CEOs Joshua Cohen and Justin Klee will engage in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 8:40 am ET, followed by a presentation at the Stifel 2023 CNS Days on March 28, 2023, at 11:00 am ET. Both events will be accessible via live webcast on the company's investor relations page.
Amylyx focuses on developing innovative treatments for neurodegenerative diseases and is headquartered in Cambridge, Massachusetts, with operations in Canada and EMEA.
Amylyx Pharmaceuticals will release its fourth quarter and full year 2022 financial results on March 13, 2023, after U.S. market close. Senior management will host a conference call at 4:30 p.m. ET to discuss these results along with other company updates. Investors can access the call by dialing (833) 816-1395 in the U.S. or +1 (412) 317-0488 internationally, and a live audio webcast will be available in the Investor section of the company's website. The event will also be archived for 90 days.
Amylyx is focused on developing innovative treatments for the neurodegenerative disease community.
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced that Co-CEOs Joshua Cohen and Justin Klee will participate in the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00am ET. The conference will be held virtually, and a live webcast of their presentation will be available in the 'Events' section of the company's website. A replay will be accessible for 90 days post-event. Amylyx is focused on developing innovative treatments for neurodegenerative diseases, with operations based in Cambridge, Massachusetts, and across Canada and EMEA.
Amylyx Pharmaceuticals has completed enrollment for the Phase 3 clinical trial, PHOENIX, evaluating AMX0035 for treating amyotrophic lateral sclerosis (ALS). This global, placebo-controlled study enrolled 664 participants and aims to assess the treatment's safety and efficacy over 48 weeks. Topline results are expected in 2024. The trial builds on positive outcomes from the prior Phase 2 CENTAUR trial, which demonstrated significant functional benefits and potential survival advantages. The European Medicines Agency is currently reviewing the marketing application for AMX0035, with a decision anticipated in early 2023.
Amylyx Pharmaceuticals (NASDAQ: AMLX) will have Co-CEOs Joshua Cohen and Justin Klee participate in the Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022, at 3:05 p.m. ET. The conference will take place virtually, and a live webcast can be accessed on the company's investor relations website. A replay will be available for 90 days post-event. Amylyx Pharmaceuticals is dedicated to innovating treatments for the neurodegenerative community and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals (AMLX) announced significant updates, including the FDA approval and commercial launch of RELYVRIO™ for ALS treatment in the U.S. and the ongoing launch of ALBRIOZA™ in Canada. For Q3 2022, net product revenue reached $0.3 million, primarily from ALBRIOZA sales. Research and development expenses surged to $24.9 million, and general expenses rose to $29.9 million. The net loss was $53.8 million, or $0.92 per share. Cash reserves stood at $162.6 million after an upsized public offering raised $230.8 million.
FAQ
What is the current stock price of Amylyx Pharmaceuticals (AMLX)?
What is the market cap of Amylyx Pharmaceuticals (AMLX)?
